Drug Combination Details
| General Information of the Combination (ID: C96101) | |||||
|---|---|---|---|---|---|
| Name | Daunorubicin NP Info | + | Bortezomib Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Acute lymphoblastic leukemia
[ICD-11: 2B33]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Up-regulation | Expression | BCL-2 | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Cleavage | CASP3 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Cleavage | CASP8 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Cleavage | CASP9 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | Jurkat | CVCL_0065 | T acute lymphoblastic leukemia | Homo sapiens | ||
| MOLT-4 | CVCL_0013 | Adult T acute lymphoblastic leukemia | Homo sapiens | |||
| Daudi | CVCL_0008 | EBV-related Burkitt lymphoma | Homo sapiens | |||
| Experimental
Result(s) |
The combination of bortezomib and daunorubicin significantly enhanced their apoptosis inducing effect in T ALL cells, which may warrant further investigation in preclinical and clinical investigations. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | Combination of bortezomib and daunorubicin in the induction of apoptosis in T-cell acute lymphoblastic leukemia. Mol Med Rep. 2017 Jul;16(1):101-108. | |||
